ArticleProceedings of the National Academy of Sciences of the United States of America2022
IKKα-deficient lung adenocarcinomas generate an immunosuppressive microenvironment by overproducing Treg-inducing cytokines.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Oral Fungal Infection Impacts Epithelial Innate Immunity to Promote Local and Distal Squamous Cell Carcinoma Progression.Cancer research · 2026Article
- The IKKα-regulated microRNA miR-9-5p mediates lung cancer growth and invasiveness via CDH1/Wnt/β-catenin signalling.Cell death discovery · 2026Article
- The roles of IKKα in normal physiology and cancer.Cell communication and signaling : CCS · 2026Review
- Regulatory B cell-related gene signature predicts prognosis and immune landscape in head and neck squamous cell carcinoma.Frontiers in immunology · 2026Article
- Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1.Nature communications · 2025Article
- Probing the metabolic regulator and candidate tumor suppressor ALDH1L1 as a target for non-small cell lung cancer gene therapy.Molecular therapy. Oncology · 2025Article
- Regulatory T cells in cancer anti-PD-(L)1 therapy.Human cell · 2025Review
- Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.International journal of molecular sciences · 2024Review
- Downstream STING pathways IRF3 and NF-κB differentially regulate CCL22 in response to cytosolic dsDNA.Cancer gene therapy · 2024Article
- Circulating Regulatory T Cells: A Novel Marker Associated with Liver Metastasis and the Treatment Response of Transarterial Embolization in Gastroenteropancreatic Neuroendocrine Tumors.Neuroendocrinology · 2024Article
- TNFR1 and TNFR2, Which Link NF-κB Activation, Drive Lung Cancer Progression, Cell Dedifferentiation, and Metastasis.Cancers · 2023Review
- Comparison of EMT-Related and Multi-Drug Resistant Gene Expression, Extracellular Matrix Production, and Drug Sensitivity in NSCLC Spheroids Generated by Scaffold-Free and Scaffold-Based Methods.International journal of molecular sciences · 2022Article
- A TNFR1-UBCH10 axis drives lung squamous cell carcinoma dedifferentiation and metastasis through a cell-autonomous signaling loop.Cell death & disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Na-Young SongLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702.
Xin LiLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702.
Buyong MaLaboratory of Cancer Immunometabolism, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.ORCID 0000-0002-7383-719X
Jami Willette-BrownLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702.
Feng ZhuLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702.
Chengfei JiangCardiovascular Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892.
Ling SuCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Jyoti ShettyCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Yongmei ZhaoCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Gongping ShiLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702.ORCID 0000-0001-8432-8553
Sayantan BanerjeeLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702.
Xiaolin WuCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Bao TranCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Ruth NussinovLaboratory of Cancer Immunometabolism, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Michael KarinLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093 karinoffice@health.ucsd.edu huy2@mail.nih.gov.ORCID 0000-0002-2758-6473
Yinling HuLaboratory of Cancer Immunometabolism, Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21702; karinoffice@health.ucsd.edu huy2@mail.nih.gov.ORCID 0000-0002-4795-8537
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USNational Heart Lung and Blood Institute · USUniversity of California San Diego · US
Funding
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8MProtein Structure, Stability, and Amyloid FormationZIABC010440 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSINOV, RUTH · 2009 to 2025
$11.8MFunctions of IKK&945; in Skin Homeostasis and Skin TumorigenesisZIABC011212 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HU, YINLING · 2009 to 2025
$11.0MBiomolecular Recognition and Binding MechanismsZIABC010441 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NUSSINOV, RUTH · 2009 to 2025
$9.4MRole of IKK alpha in lung squamous cell carcinoma developmentZIABC011391 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HU, YINLING · 2011 to 2025
$9.1MNF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of InflammationR37AI043477 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Karin · 2018 to 2026
$6.0MImmunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitorsU01AA027681 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EL-KHOUEIRY, ANTHONY BOUTROS, KARIN, MICHAEL · 2018 to 2022
$3.6MIntramural NIH HHS ZIA BC011212NIAAA NIH HHS P50 AA011999NIAAA NIH HHS U01 AA027681NIAID NIH HHS R37 AI043477
Abstract
The tumor microenvironment (TME) provides potential targets for cancer therapy. However, how signals originating in cancer cells affect tumor-directed immunity is largely unknown. Deletions in the
Indexed as
Adenocarcinoma of LungAnimalsCD4-Positive T-LymphocytesCell Line, TumorCell Transformation, NeoplasticCytokinesHumansI-kappa B KinaseImmunosuppression TherapyLung NeoplasmsMacrophagesMiceMice, Inbred C57BLMonocytesReceptors, Tumor Necrosis Factor, Type IISignal TransductionCytokinesI-kappa B KinaseReceptors, Tumor Necrosis Factor, Type IIimmunosuppressive responseinflammationlung cancerNK-κB signalingTreg cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.